Anthem Biosciences IPO GMP Surges: Will It Deliver Big Listing Gains?

Anthem Biosciences IPO GMP has become one of the most discussed topics in the Indian stock market this week. With the IPO set to open on July 14, 2025, retail and institutional investors alike are closely watching the grey market for early cues on listing gains.

In this article, we decode everything you need to know about the Anthem Biosciences IPO GMP, including the latest figures, investor sentiment, sector outlook, valuation metrics, and whether this IPO is worth subscribing to.

---

What Is Anthem Biosciences?

Anthem Biosciences is one of India’s leading Contract Development and Manufacturing Organizations (CDMOs), serving global pharmaceutical and biotechnology companies. It offers comprehensive solutions from pre-clinical research to commercial-scale manufacturing.

With India becoming a global hub for pharma outsourcing, Anthem’s business model is well-positioned to benefit from rising international demand.

The company has reported over ₹1,900 crore in revenue and ₹450 crore in net profit for FY24. This strong financial performance has added to the positive buzz around its IPO.

---

IPO Details at a Glance

• IPO Opening Date: July 14, 2025

• IPO Closing Date: July 16, 2025

• Price Band: ₹540 – ₹570 per share

• Issue Size: ₹3,395 crore (Offer for Sale only)

• Lot Size: 26 shares

• Listing On: NSE and BSE

The IPO consists entirely of an Offer for Sale (OFS), meaning no fresh equity will be issued. Instead, existing investors and promoters are selling their shares.

---

Anthem Biosciences IPO GMP: What the Grey Market Says

Anthem Biosciences IPO GMP has been trending upwards since the company announced its IPO dates. As of July 14, the GMP stands between ₹85 to ₹100.

This means that in the unlisted market, the shares are being traded at a premium of ₹85–₹100 over the upper price band of ₹570. If the stock lists at this premium, the listing price could be around ₹655–₹670, implying a potential 15–17% gain on day one.

This surge in GMP is being interpreted as a sign of strong demand from retail and high-net-worth investors.

---

Why Is Anthem Biosciences IPO GMP So High?

Several key factors are contributing to the strong GMP:

1. Robust Financials: With stable revenues and high profitability, the company is financially healthy.

2. Attractive Sector: The CDMO segment is growing globally, and India is a preferred outsourcing destination.

3. Strong Anchor Book: The company raised ₹1,016 crore from prominent institutional investors.

4. Low Valuation Compared to Peers: Its Price-to-Earnings (P/E) ratio is reasonable for its growth potential.

5. High Market Sentiment: Investors are optimistic, and market momentum supports new listings.

---

Anchor Investors Add Credibility

Ahead of the IPO, Anthem Biosciences allotted shares worth ₹1,016 crore to anchor investors. Notable participants included:

• Abu Dhabi Investment Authority (ADIA)

• Amundi Funds

• HDFC Mutual Fund

• ICICI Prudential AMC

• Societe Generale

This strong institutional interest lends credibility to the IPO and further supports the high GMP.

---

How Does It Compare to Peers?

Let’s take a look at how Anthem compares to other listed CDMO players:

Anthem Biosciences IPO GMP reflects the fact that, compared to listed peers, it offers strong earnings at a relatively fair valuation.

---

Is the GMP a Reliable Indicator?

While Anthem Biosciences IPO GMP offers a strong early signal, it’s important to remember that GMP is unofficial and unregulated. Prices in the grey market can fluctuate quickly due to:

• Market volatility

• Global cues

• Subscription data during IPO days

• Institutional activity

Hence, while a high GMP is encouraging, it should not be the only metric to rely on when applying for an IPO.

---

Key Strengths of Anthem Biosciences

1. Diverse Global Client Base: Anthem serves both Indian and international pharma majors.

2. End-to-End Services: Offers drug discovery, development, and commercial manufacturing under one roof.

3. Regulatory Approvals: Facilities are US FDA, WHO, and EU GMP approved.

4. R&D Capability: Over 450 scientists driving innovation.

5. Stable Margins: High EBITDA margins and consistent profits.

---

Risks You Should Know

Every IPO comes with risks, and despite the strong Anthem Biosciences IPO GMP, here are some red flags to be aware of:

• No Fresh Issue: The IPO doesn’t bring in new capital for business expansion.

• Sector Dependence: Over-reliance on global pharma outsourcing trends.

• Regulatory Risk: CDMO businesses are subject to strict international regulations.

---

Who Should Subscribe?

✔️ Retail Investors:

If you’re looking for short-term listing gains, the high GMP suggests potential upside.

✔️ Long-Term Investors:

The company’s strong financials, sectoral strength, and client base make it suitable for portfolio inclusion, especially with a 2–3 year view.

⚠️ Conservative Investors:

If you avoid IPOs with no fresh capital or are concerned about global volatility, you may want to wait and watch post-listing.

---

Expert Sentiment

Several brokerage firms and market analysts have given a “Subscribe” rating based on:

• High GMP

• Strong anchor book

• Financial strength

• Sector tailwinds

The listing is expected to be oversubscribed across all investor categories.

---

Final Word

Anthem Biosciences IPO GMP shows promising signs for both short-term traders and long-term investors. A GMP between ₹85 and ₹100 indicates a strong opening premium, driven by robust financials, sector potential, and strong institutional interest.

However, investors should still weigh the pros and cons before applying. While GMP is a helpful signal, solid research on the company’s fundamentals, competitive positioning, and long-term growth is essential.

Source: Moneycontrol

Suggestions: ITR Filing Latest Updates 2025: Deadline Extended, Refunds Delayed, and New Compliance Rules Announced